Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26319
Abstract: die of BM failure. This similarity to MDS-Mut in clinical presentation and natural history raises the possibility that MDS-NDM cases may harbor mutations in genes not covered in standard sequencing panels, or not detected in… read more here.
Keywords: frail patients; dexamethasone frail; pomalidomide dexamethasone; plus pomalidomide ... See more keywords
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26480
Abstract: In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D‐Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma… read more here.
Keywords: pomalidomide dexamethasone; daratumumab; health; relapsed refractory ... See more keywords
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32178
Abstract: The efficacy of daratumumab (DARA) both as a monotherapy and in combination with standard‐of‐care regimens in multiple myeloma (MM) has been established in clinical trials. This article presents a retrospective analysis of the safety and… read more here.
Keywords: daratumumab pomalidomide; efficacy; pomalidomide dexamethasone; efficacy daratumumab ... See more keywords
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Hematology"
DOI: 10.1007/s12185-024-03800-5
Abstract: This post-marketing surveillance assessed the safety and effectiveness of isatuximab plus pomalidomide and dexamethasone (Isa-Pd) for relapsed or refractory multiple myeloma (RRMM) during real-world use in Japan. Data from 211 individuals with RRMM treated with… read more here.
Keywords: marketing surveillance; post marketing; refractory multiple; relapsed refractory ... See more keywords
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2022.2082725
Abstract: ABSTRACT Objectives There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination with pomalidomide and dexamethasone (IsaPomDex). In this UK-wide retrospective study, we set out to… read more here.
Keywords: pomalidomide dexamethasone; infection; myeloma; patients treated ... See more keywords
Selinexor in combination with pomalidomide and dexamethasone for the treatment of primary plasma cell leukemia with 1q21+ abnormality: A case report
Sign Up to like & getrecommendations! Published in 2024 at "Medicine"
DOI: 10.1097/md.0000000000040447
Abstract: Rationale: Primary plasma cell leukemia is a rare and highly aggressive malignancy of the blood system, with rapid disease progression and a high early mortality rate. Currently, there is no recognized therapeutic regimen, leading to… read more here.
Keywords: plasma cell; cell leukemia; cell; pomalidomide dexamethasone ... See more keywords
Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15628
Abstract: A population pharmacokinetic (PPK) model was developed to characterize pharmacokinetics (PK) of subcutaneous or intravenous daratumumab administration in a new indication (i.e., combination with pomalidomide and dexamethasone [D‐Pd] in patients with relapsed or refractory multiple… read more here.
Keywords: exposure response; pomalidomide dexamethasone; relapsed refractory; refractory multiple ... See more keywords
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of haematology"
DOI: 10.1111/bjh.18772
Abstract: Lenalidomide maintenance in myeloma is well established. Nevertheless, pomalidomide could provide an alternative. Myeloma patients in first relapse, initially treated in the Intergroupe Francophone du Myélome (IFM) 2009 trial, and subsequently in the IFM 2013-01… read more here.
Keywords: pomalidomide dexamethasone; progression; myeloma; therapy ... See more keywords
Abstract 6046: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-6046
Abstract: Recent literature has shown that loss-of-function of BRD9, a component of the noncanonical SWI/SNF (ncSWI/SNF) complex, mediated by RNA interference or by BRD9 degrader compounds can inhibit multiple myeloma (MM) cell lines and primary MM… read more here.
Keywords: multiple myeloma; degrader; cell; brd9 ... See more keywords
Long-Term Effectiveness and Safety of Isatuximab in Combination with Pomalidomide and Dexamethasone in a Japanese Patient with Refractory Multiple Myeloma and 1q21 Amplification: A Case Report.
Sign Up to like & getrecommendations! Published in 2025 at "Case reports in oncology"
DOI: 10.1159/000543347
Abstract: Abstract Introduction: In the ICARIA-MM trial, isatuximab plus pomalidomide-dexamethasone (Pd) significantly prolonged progression-free survival, compared with Pd alone, in patients with relapsed or refractory multiple myeloma (RRMM), including those with gain or amplification of chromosome… read more here.
Keywords: multiple myeloma; refractory multiple; amplification; case ... See more keywords
Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210284
Abstract: Aim To analyze the efficacy and safety of Ixazomib, pomalidomide and dexamethasone (IxaPD) regimen in patients with refractory and relapsed multiple myeloma（RRMM）. Methods Clinical data of RRMM patients were prospectively collected from 5 centers in… read more here.
Keywords: multiple myeloma; treatment; refractory; ixazomib pomalidomide ... See more keywords